Ganglioside as a neurotrophic drug has been hitherto widely used in China, although Guillain-Barré syndrome (GBS) following intravenous ganglioside treatment was reported in Europe several decades ago, leading to its withdrawal from European market. We identified 7 patients who developed GBS after intravenous use of gangliosides (the ganglioside + group) and compared their clinical data with those of 77 non-ganglioside-associated GBS patients (the ganglioside − group) in 2013, aiming at gaining the distinct features of ganglioside-associated GBS. Although the mean age, the protein levels in cerebrospinal fluid (CSF) and the frequency of cranial nerve involvement were similar between the two groups, the Hughes Functional Grading Scale (HFGS) score and the Medical Research Council (MRC) sum score at nadir significantly differed (4.86 versus 3.64; 7.71 versus 36.87, both p b 0.001), indicating a higher disease severity of gangliosideassociated GBS. This was further evidenced by a significantly higher ratio of patients with ganglioside-associated GBS who required mechanical ventilation (85.71% versus 15.58%, p b 0.01). The short-term prognosis of ganglioside-associated GBS, as measured by the HFGS score and the MRC sum score at discharge, was poorer (4.29 versus 2.82; 17.29 versus 45.96, both p b 0.001). All the patients in the ganglioside + group presented an axonal form of GBS, namely acute motor axonal neuropathy (AMAN). When compared with the AMAN patients in the ganglioside − group, more severe functional deficits at nadir and poorer recovery after standard treatment were still prominent in ganglioside-associated GBS. Anti-GM1 and anti-GT1a antibodies were detectable in patients with AMAN while not in patients with the demyelinating subtype of GBS. The concentrations of these antibodies in patients with AMAN were insignificantly different between the ganglioside + and the ganglioside − groups. In sum, ganglioside-associated GBS is a devastating side effect of intravenous use of ganglioside, which usually manifests a more severe clinical course and poorer outcome.
More severe manifestations and poorer short-term prognosis of ganglioside-associated Guillain-Barré syndrome in northeast China Ganglioside as a neurotrophic drug has been hitherto widely used in China, although Guillain-Barré syndrome (GBS) following intravenous ganglioside treatment was reported in Europe several decades ago, leading to its withdrawal from European market. We identified 7 patients who developed GBS after intravenous use of gangliosides (the ganglioside + group) and compared their clinical data with those of 77 non-ganglioside-associated GBS patients (the ganglioside − group) in 2013, aiming at gaining the distinct features of ganglioside-associated GBS. Although the mean age, the protein levels in cerebrospinal fluid (CSF) and the frequency of cranial nerve involvement were similar between the two groups, the Hughes Functional Grading Scale (HFGS) score and the Medical Research Council (MRC) sum score at nadir significantly differed (4.86 versus 3.64; 7.71 versus 36.87, both p b 0.001), indicating a higher disease severity of gangliosideassociated GBS. This was further evidenced by a significantly higher ratio of patients with ganglioside-associated GBS who required mechanical ventilation (85.71% versus 15.58%, p b 0.01). The short-term prognosis of ganglioside-associated GBS, as measured by the HFGS score and the MRC sum score at discharge, was poorer (4.29 versus 2.82; 17.29 versus 45.96, both p b 0.001). All the patients in the ganglioside + group presented an axonal form of GBS, namely acute motor axonal neuropathy (AMAN). When compared with the AMAN patients in the ganglioside − group, more severe functional deficits at nadir and poorer recovery after standard treatment were still prominent in ganglioside-associated GBS. Anti-GM1 and anti-GT1a antibodies were detectable in patients with AMAN while not in patients with the demyelinating subtype of GBS. The concentrations of these antibodies in patients with AMAN were insignificantly different between the ganglioside + and the ganglioside − groups. In sum, ganglioside-associated GBS is a devastating side effect of intravenous use of ganglioside, which usually manifests a more severe clinical course and poorer outcome. Objective: To study if smoking alters the gene expression in blood cells from MS patients. Methods: We collected blood samples and isolated peripheral blood mononuclear cells (PBMC) from 17 smoking and 16 non-smoking MS patients. RNA expression was measured using the Affymetrix Human Gene 1.0 ST Gene Chip array. Gene expression was analyzed by ANCOVA analysis, using Partek Genomics Suite 6.6 software and relevant pathways and networks were conducted using Ingenuity Pathway Analysis (IPA). Results: We corrected data for age and sex, and found 19 annotated genes differentially expressed between smoking and non-smoking MS patients. After false discovery rate correction, 2 genes were still differentially expressed. G-protein coupled receptor 15 (GPR15), which is expressed in CD4 cells and alveolar macrophages, was up-regulated by a 3.6 fold change, and leucine-rich repeat neuronal protein 3 (LRRN3), which is highly expressed in brain tissue, was up-regulated by a 2.1 fold change. Analysis of the differentially expressed genes revealed a network dominated by proinflammatory molecules including CD4, NF-kappaB and IL2, and associated network functions being infectious diseases, cellular movement and immune cell trafficking. Conclusion: We find that smoking is associated with increased expression of the GPR15 and LRRN3 genes in PBMC from MS patients. Furthermore, network analysis of 19 differentially expressed genes revealed molecules linked to T cell activation and innate immunity. This indicates altered innate and adaptive immune activation in smoking MS patients, which should be further investigated. doi:10.1016/j.jneuroim.2014.08.131
